Equity Details
Price & Market Data
Price: $31.15
Daily Change: -$0.57 / 1.83%
Daily Range: $30.82 - $31.79
Market Cap: $3,636,428,544
Daily Volume: 1,328,227
Performance Metrics
1 Week: 0.03%
1 Month: -10.54%
3 Months: 8.94%
6 Months: -14.82%
1 Year: 10.67%
YTD: -10.97%
About Viking Therapeutics, Inc. (VKTX)
Stay informed about Viking Therapeutics, Inc. (VKTX). Price: 31.15, daily change: -$0.57 / 1.83%. Market cap: 3,636,428,544. Detailed performance for all key periods.
Company Details
Employees: 53
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.